CY1106305T1 - Ενεσιμη συνθεση αποθεματος πepιλαμβανουσα κρυσταλλους ιλοπepιδονης - Google Patents

Ενεσιμη συνθεση αποθεματος πepιλαμβανουσα κρυσταλλους ιλοπepιδονης

Info

Publication number
CY1106305T1
CY1106305T1 CY20061101867T CY061101867T CY1106305T1 CY 1106305 T1 CY1106305 T1 CY 1106305T1 CY 20061101867 T CY20061101867 T CY 20061101867T CY 061101867 T CY061101867 T CY 061101867T CY 1106305 T1 CY1106305 T1 CY 1106305T1
Authority
CY
Cyprus
Prior art keywords
crystals
pepilamvanus
ilopepidone
deposit composition
size
Prior art date
Application number
CY20061101867T
Other languages
English (en)
Inventor
Dierk Wieckhusen
Alexandra Glausch
Markus Ahlheim
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9940486&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1106305(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CY1106305T1 publication Critical patent/CY1106305T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Ενέσιμη σύνθεση αποθέματος περιλαμβάνουσα κρυστάλλους έχοντες τη Δομή (I) όπου το R είναι (FII) και η τιμή Χ50 των κρυστάλλων είναι από 1 έως 200 μm. Οι συνθέσεις οι περιέχουσες κρυστάλλους ιλοπεριδόνης ή του μεταβολίτη της έχουν τα ακόλουθα πλεονεκτήματα: (i) η απελευθέρωση των κρυστάλλων στο πλάσμα μπορεί να συσχετισθεί με το μέγεθος των κρυστάλλων˙ (ii) η απορρόφηση των κρυστάλλων στο πλάσμα μπορεί να συσχετισθεί με το μέγεθος των κρυστάλλων˙ (iii) το μέγεθος σωματιδίων των κρυστάλλων μπορεί να ελεγχθεί δια μηχανικής και/ή αλέσεως κρυστάλλων˙ και (iν) οι κρύσταλλοι είναι σταθεροί κατά την αποθήκευση και σταθεροί στις διαδικασίες αποστειρώσεως, όπως η ακτινοβόληση γάμα.
CY20061101867T 2002-07-15 2006-12-29 Ενεσιμη συνθεση αποθεματος πepιλαμβανουσα κρυσταλλους ιλοπepιδονης CY1106305T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0216416.8A GB0216416D0 (en) 2002-07-15 2002-07-15 Organic compounds
PCT/EP2003/007619 WO2004006886A2 (en) 2002-07-15 2003-07-14 Injectable depot formulation comprising crystals of iloperidone

Publications (1)

Publication Number Publication Date
CY1106305T1 true CY1106305T1 (el) 2011-10-12

Family

ID=9940486

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20061101867T CY1106305T1 (el) 2002-07-15 2006-12-29 Ενεσιμη συνθεση αποθεματος πepιλαμβανουσα κρυσταλλους ιλοπepιδονης

Country Status (16)

Country Link
US (5) US20050250813A1 (el)
EP (1) EP1523335B1 (el)
JP (2) JP5392961B2 (el)
AT (1) ATE348635T1 (el)
AU (1) AU2003281154B2 (el)
CA (1) CA2492467C (el)
CY (1) CY1106305T1 (el)
DE (1) DE60310564T2 (el)
DK (1) DK1523335T3 (el)
ES (1) ES2279153T3 (el)
GB (1) GB0216416D0 (el)
HK (1) HK1076029A1 (el)
NZ (1) NZ537598A (el)
PT (1) PT1523335E (el)
WO (1) WO2004006886A2 (el)
ZA (1) ZA200410323B (el)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101912367A (zh) 2001-10-30 2010-12-15 诺瓦提斯公司 伊潘立酮和星状聚合物的贮库制剂
GB0216416D0 (en) * 2002-07-15 2002-08-21 Novartis Ag Organic compounds
GEP20115205B (en) 2003-10-23 2011-04-26 Otsuka Pharma Co Ltd Controlled release sterile injectable aripiprazole formulation and method
CA2582022C (en) 2004-09-30 2021-05-18 Vanda Pharmaceuticals, Inc. Methods for the administration of iloperidone
US20090306137A1 (en) 2006-05-22 2009-12-10 Wolfgang Curt D Treatment for depressive disorders
US8198305B2 (en) 2007-04-13 2012-06-12 Concert Pharmaceuticals Inc. 1,2-benzisoxazol-3-yl compounds
US9457026B2 (en) 2007-07-31 2016-10-04 Otsuka Pharmaceutical Co., Ltd. Methods for producing aripiprazole suspension and freeze-dried formulation
US8652776B2 (en) 2007-09-10 2014-02-18 Vanda Pharmaceuticals, Inc. Prediction of QT prolongation based on SNP genotype
ES2483366T3 (es) 2007-12-13 2014-08-06 Vanda Pharmaceuticals Inc. Método y composición para el tratamiento de una afección mediada por el receptor de serotonina
BRPI0820993A2 (pt) 2007-12-13 2017-05-09 Vanda Pharmaceuticals Inc método e composição para tratar uma condição mediada por alfa adrenoceptor
WO2010031497A1 (en) * 2008-09-19 2010-03-25 Miklos Vertessy New process for the preparation of iloperidone
CN101822673B (zh) * 2009-03-04 2013-09-18 北京德众万全药物技术开发有限公司 一种含有伊潘立酮的固体药物组合物
US20120136050A1 (en) 2009-07-16 2012-05-31 Vanda Pharmaceuticals Inc. Use of a melatonin agonist for the treatment of sleep disorders including primary insomnia
CN102395582A (zh) * 2009-09-19 2012-03-28 浙江华海药业股份有限公司 伊潘立酮的一种制备方法及结晶方法
CN102030744B (zh) * 2009-09-30 2013-04-17 天津药物研究院 伊潘立酮晶体、其制备方法及药物组合物
WO2011055188A1 (en) * 2009-11-05 2011-05-12 Orchid Chemicals And Pharmaceuticals Limited An improved process for the preparation of iloperidone
MX2012007365A (es) * 2009-12-23 2012-08-15 Lupin Ltd Composiciones farmaceuticas de liberacion lenta de iloperidona.
CN102108081A (zh) * 2009-12-25 2011-06-29 重庆医药工业研究院有限责任公司 伊潘立酮的新晶型及其制备方法
HUE030566T2 (en) 2010-01-11 2017-05-29 Inotek Pharmaceuticals Corp Combination, kit and method for reducing intraocular pressure
SG184221A1 (en) 2010-03-26 2012-10-30 Inotek Pharmaceuticals Corp Method of reducing intraocular pressure in humans using n6 -cyclopentyladenosine (cpa), cpa derivatives or prodrugs thereof
CN101822674B (zh) * 2010-05-27 2015-03-11 北京德众万全医药科技有限公司 一种伊潘立酮药物组合物及其制备方法
CN103249416B (zh) * 2010-10-18 2019-06-04 大日本住友制药株式会社 注射用缓释制剂
WO2012063269A2 (en) 2010-11-12 2012-05-18 Cadila Healthcare Limited Process for preparing iloperidone
WO2012090138A1 (en) 2010-12-27 2012-07-05 Ranbaxy Laboratories Limited Processes for the preparation of iloperidone
CN102680636A (zh) * 2011-03-11 2012-09-19 天津药物研究院 一种伊潘立酮原料药及其中间体的质量控制方法
MX2014009086A (es) 2012-01-26 2015-06-05 Inotek Pharmaceuticals Corp Polimorfos anhidros de nitrato de [ (2r,3s,4r,5r) -5- (6- (ciclopentilamino) -9h-purin-9-il) -3,4-dihidroxitetra-hidrofuran- 2-il) ] metilo y procesos para su preparación.
ES2646197T3 (es) 2012-01-26 2017-12-12 Vanda Pharmaceuticals Inc. Tratamiento de trastornos del ritmo circadiano
US11918557B2 (en) 2012-01-26 2024-03-05 Vanda Pharmaceuticals Inc. Treatment of circadian rhythm disorders
CN102659771B (zh) * 2012-04-18 2013-11-27 吉林三善恩科技开发有限公司 一种伊潘立酮药物共晶及其制备方法
CN102633786B (zh) * 2012-04-18 2013-11-27 吉林三善恩科技开发有限公司 一种伊潘立酮药物共晶及其制备方法
RU2632889C2 (ru) 2012-05-18 2017-10-11 Ванда Фармасьютиклз Инк. Метаболиты (1r-транс)-n-[[2-(2,3-дигидро-4-бензофуранил)циклопропил]-метил]пропанамида
IL266159B1 (en) 2012-12-18 2024-03-01 Vanda Pharmaceuticals Inc Treatment of circadian rhythm disorders
KR20150139501A (ko) * 2013-03-15 2015-12-11 이노텍 파마슈티컬스 코포레이션 안과용 제형
US10376487B2 (en) 2013-11-12 2019-08-13 Vanda Pharmaceuticals Inc. Method of treatment
US11090285B2 (en) 2013-11-12 2021-08-17 Vanda Pharmaceuticals Inc Treatment of circadian rhythm disorders
CN103599074A (zh) * 2013-11-26 2014-02-26 重庆医药工业研究院有限责任公司 一种伊潘立酮缓释微球及其制备方法
CN107249586A (zh) 2015-02-17 2017-10-13 万达制药公司 用于治疗精神分裂症的伊潘立酮
US11071728B2 (en) 2015-12-11 2021-07-27 Vanda Pharmaceuticals Inc. Treatment of schizophrenia
CN106831741B (zh) * 2016-12-28 2019-08-23 北京医药集团有限责任公司 一种伊潘立酮超细粉体的制备方法
US10935106B2 (en) * 2018-06-14 2021-03-02 Serapid, Inc. Block chain with monolithic links
JP2022510454A (ja) * 2018-12-04 2022-01-26 バンダ・ファーマシューティカルズ・インコーポレイテッド イロペリドンの持効性投与
US20200171018A1 (en) * 2018-12-04 2020-06-04 Vanda Pharmaceuticals Inc. Depot administration of iloperidone
US11607408B2 (en) 2019-10-15 2023-03-21 Vanda Pharmaceuticals Inc. Method of treatment of schizophrenia

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB216416A (en) 1923-09-06 1924-05-29 James Baker And Sons Ltd Improvements in boots and shoes
JPS53108940A (en) * 1976-10-28 1978-09-22 Hoechst France Optically active nncarbethoxyyalphaa aminophenyl acetic acids * its preparation and its use for preparation of optically active alpha aminoophenylacetic acid
CH656884A5 (de) 1983-08-26 1986-07-31 Sandoz Ag Polyolester, deren herstellung und verwendung.
DE3345355A1 (de) * 1983-12-15 1985-06-27 Hoechst Ag, 6230 Frankfurt Verfahren zur racematspaltung bicyclischer imino-(alpha)-carbonsaeureester
DE3511587A1 (de) 1985-03-27 1986-10-02 Schering AG, Berlin und Bergkamen, 1000 Berlin Glykoester des estradiols und estriols
US4886370A (en) 1987-08-25 1989-12-12 Nkk Corporation Method for detecting a state of substance existing in pipe
ATE126512T1 (de) * 1989-05-19 1995-09-15 Hoechst Roussel Pharma N-(aryloxyalkyl)heteroarylpiperidine und - heteroarylpiperazine, verfahren zu ihrer herstellung und ihre verwendung als medikamente.
US5776963A (en) 1989-05-19 1998-07-07 Hoechst Marion Roussel, Inc. 3-(heteroaryl)-1- (2,3-dihydro-1h-isoindol-2-yl)alkyl!pyrrolidines and 3-(heteroaryl)-1- (2,3-dihydro-1h-indol-1-yl)alkyl!pyrrolidines and related compounds and their therapeutic untility
US5364866A (en) 1989-05-19 1994-11-15 Hoechst-Roussel Pharmaceuticals, Inc. Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analetics
US5538739A (en) 1989-07-07 1996-07-23 Sandoz Ltd. Sustained release formulations of water soluble peptides
AU636043B2 (en) * 1990-06-04 1993-04-08 Schering Corporation Method for preparing interferon alpha-2 crystals
ZA933134B (en) * 1992-05-08 1993-11-30 Akzo Nv Depot preparation
CA2148823C (en) 1992-11-17 1999-03-09 Welfide Corporation Sustained release microsphere preparation containing antipsychotic drug and production process thereof
DE69434258T2 (de) 1993-11-19 2006-01-19 Janssen Pharmaceutica N.V. Mikroverkapselte 1,2-benzazole
US5902882A (en) * 1996-04-17 1999-05-11 Hoffmann-La Roche Inc. Assymetric synthesis of azepines
TW487572B (en) * 1996-05-20 2002-05-21 Janssen Pharmaceutica Nv Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters
BR9809162A (pt) * 1997-05-26 2000-08-01 Akzo Nobel Nv Sal de trans-5-cloro-2, 3, 3a, 12b-tetrahidro-2-metil-1h-dibenz [2,3:6,7] oxepino[4,5-c] pirrol e agente formador de sal, composto, composição farmacêutica, e, preparação de injeção armazenável
UA72189C2 (uk) * 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
US5955459A (en) * 1997-11-26 1999-09-21 Neuromedica, Inc. Fatty acid-antipsychotic compositions and uses thereof
US6541606B2 (en) * 1997-12-31 2003-04-01 Altus Biologics Inc. Stabilized protein crystals formulations containing them and methods of making them
DE19816070A1 (de) 1998-04-09 1999-10-14 Aventis Res & Tech Gmbh & Co Retardtablette hergestellt aus linearen wasserunlöslichen Polysacchariden
CN1367697A (zh) 1998-10-16 2002-09-04 詹森药业有限公司 改善认识的疗法
US6509310B1 (en) 2000-06-01 2003-01-21 Huish Detergents, Inc. Compositions containing α-sulfofatty acid esters and method of making the same
WO2001092334A1 (en) 2000-06-02 2001-12-06 Novo Nordisk A/S Glucose dependent release of insulin from glucose sensing insulin derivatives
PT2305656E (pt) * 2001-08-31 2013-01-10 Novartis Ag Isómeros óticos de um metabolito de iloperidona
CN101912367A (zh) * 2001-10-30 2010-12-15 诺瓦提斯公司 伊潘立酮和星状聚合物的贮库制剂
GB0216416D0 (en) * 2002-07-15 2002-08-21 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
CA2492467C (en) 2010-03-16
EP1523335A2 (en) 2005-04-20
DE60310564D1 (de) 2007-02-01
HK1076029A1 (en) 2006-01-06
NZ537598A (en) 2006-07-28
JP5670698B2 (ja) 2015-02-18
AU2003281154A1 (en) 2004-02-02
US8227488B2 (en) 2012-07-24
US20130012542A1 (en) 2013-01-10
WO2004006886A3 (en) 2004-02-19
US20090099232A1 (en) 2009-04-16
JP2005533093A (ja) 2005-11-04
WO2004006886A2 (en) 2004-01-22
US20120156264A1 (en) 2012-06-21
JP2011016849A (ja) 2011-01-27
PT1523335E (pt) 2007-02-28
EP1523335B1 (en) 2006-12-20
DK1523335T3 (da) 2007-01-29
CA2492467A1 (en) 2004-01-22
US20110212141A1 (en) 2011-09-01
AU2003281154B2 (en) 2006-10-12
US8614232B2 (en) 2013-12-24
DE60310564T2 (de) 2007-10-04
US20050250813A1 (en) 2005-11-10
US8293765B2 (en) 2012-10-23
ZA200410323B (en) 2006-06-28
ES2279153T3 (es) 2007-08-16
ATE348635T1 (de) 2007-01-15
JP5392961B2 (ja) 2014-01-22
GB0216416D0 (en) 2002-08-21

Similar Documents

Publication Publication Date Title
CY1106305T1 (el) Ενεσιμη συνθεση αποθεματος πepιλαμβανουσα κρυσταλλους ιλοπepιδονης
AR034422A1 (es) Una composicion de resina de polipropileno que contiene un derivado de acido trimesico, un metodo para proveer una resina con un valor de niebla menor de 62%, un uso del derivado de acido trimesico como agente reductor de niebla, mezclas que contienen los derivados de acidos trimesicos, composicione
RS53638B1 (en) CRYSTAL SOLVATES OF DERIVATIVES (1S) -1,5-ANHYDRO-1-C- (3 - ((PHENYL) METHYL) PHENYL) -D-GLUCITOL WITH ALCOHOLS AS INHIBITORS OF SGLT2 FOR TREATMENT OF DIABETES
CO5251462A1 (es) Composicion de administracion oral
ECSP034865A (es) Resolución óptica de (1-benzilo-4-metilopiperidina-3-il)-metilamina y su uso para la preparación de derivados de pirrolo 2,3-pirimidina como inhibidores de proteina quinasas
PE20081362A1 (es) DERIVADOS MORFOLINO PIRIMIDINA COMO INHIBIDORES DE mTOR QUINASA Y PI3K
CO5690130A1 (es) Derivados de eter biarilico que presentan actividad como inhibidores de la recaptacion de monoaminas para el tratamiento del snc
AR066793A1 (es) Agentes de 3- ciano-4-triazolil fenilsoxazolina para el control de plagas de invertebrados
AR046308A1 (es) Derivados amida
CO5150150A1 (es) 4-oxo-1,4-dihidro-3-quinoleincarboxamidas como agentes antivirales
PE20040071A1 (es) Indazoles substituidos, composiciones que los contienen, procedimiento de fabricacion y utilizacion
AR069412A1 (es) Derivados de pirimidina, proceso para prepararlos, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades virales, bacterianas y alergicas, entre otras.
DK1401837T3 (da) Purinderivater som A2B-adenosinreceptorantagonister
PE20070179A1 (es) Derivados de purina como agonistas del receptor de adenosina a2
CY1111697T1 (el) Νεες συνθεσεις οι οποιες περιεχουν ενωσεις κινολινης
CY1106679T1 (el) Αζαδικυκλικες ετεροκυκλικες ενωσεις ως τροποποιητες κανναβινοειδους υποδοχεα
MX2009013335A (es) Derivados de piperidina/piperazina.
CO5231142A1 (es) TIADIAZOLA COMO INGREDIENTE ACTIVO, EN COMBINACIàN CON AL ME NOS UN FUNGICIDA SELECCIONADO DE LOS COMPONENTES QUE TIENE UNA ACTIVIDAD FUNGICIDA CONTRA LAS ENFERMEDADES DE LAS PLAN- TAS Y UN METODO PARA EL USO DEL MISMO
PE20060381A1 (es) Analogos de dipeptidos inhibidores de la hepatitis c
PE20060648A1 (es) Procesos para la preparacion de 2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolinas sustituidas
PE20090511A1 (es) Imidazopiridinonas
CO6311078A2 (es) Compuestos heterociclicos que contienen dos o más heteroanillos, que contienen átomos de nitrogeno como únicos heteroátomos en el anillo, en donde al menos un anillo es de 6 miembros con un átomo de nitrógeno, que contienen tres ó más heteroátomos, c
AR030045A1 (es) Composicion farmaceutica que contiene compuestos antibioticos de azalida , metodos para obtencion
PT1261602E (pt) Derivados imidazol-2-carboxamida como inibidores de cinase raf
AR053336A1 (es) Formas cristalinas de un compuesto de bifenilo